Biotechnology

Genprex

Genprex released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 0, actual EPS USD -0.6418

Genprex released FY2025 Q4 earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.7978 (forecast USD -29)

Genprex released FY2025 Annual Earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -17.3994 (forecast USD -135.5)

Genprex released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.9957 (forecast USD -32)

Genprex released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -26.4522

Genprex Receives Patent Grant Notice for Reqorsa Gene Therapy Combined with PD-1 Antibodies for Cancer Treatment

Genprex Inc to present positive preclinical data of Reqorsa® gene therapy at cancer treatment conference

Genprex released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -8.4708 (forecast USD -35.5)

Genprex released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -20.1258

Genprex Leads in Progress on Alpha Cell Study

Genprex Announces Positive Preclinical Results for Diabetes Candidate Drug GPX-002

Genprex Inc. Restores Compliance with NASDAQ Requirements

Genprex released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -12.9857 (forecast USD -41)

Genprex Obtains Exclusive Patent License for Reqorsa® Gene Therapy

Genprex Unveils Promising Preclinical Data for Gene Therapy REQORSA at AACR

Genprex Announces Positive Preclinical Results for Diabetes Gene Therapy

Genprex Signs Exclusive Licensing Agreement for Reqorsa Gene Therapy with NYU Langone Health

Genprex's Reqorsa® Gene Therapy Shows Promising Preclinical Results for Lung Cancer Treatment

Genprex released FY2024 Q4 earnings on April 1 (EST), actual revenue USD 0, actual EPS USD -24.8017 (forecast EPS USD -41)

Genprex released FY2024 earnings on April 1, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -266.953 (forecast USD -285)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

GNPX

LABU

ARKG

Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 at the 2026 American Society of Gene and Cell Therapy Annual Meeting. The therapy showed promising results in Type 2 diabetic mouse models, reversing hyperglycemia and improving insulin function. Genprex emphasized the therapy's potential for human application through endoscopic pancreatic delivery, marking a significant advancement towards a treatment that could provide durable glycemic control for Type 2 diabetes patients. The company focuses on gene-based treatments for serious diseases, including diabetes and cancer.

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy

SBIO

Genprex announced preclinical data at ASGCT showing that its Pdx1/MafA gene therapy (PM) effectively reversed hyperglycemia in Type 2 diabetic mice. Key findings include restored insulin secretion and improved β-cell function in PM-treated islets. Both β-cell–specific and global PM delivery methods enhanced glucose control and β-cell maturation. The company suggests that the pancreatic delivery technique is feasible for human application, indicating potential for long-term glycemic control.

TradingView

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT

OPCH

The health care sector has seen oversold stocks with RSI below 30, indicating potential buying opportunities. Key stocks include Medtronic PLC (MDT), which received CE Mark for its Stealth AXiS™ system but saw a 10% stock drop; Option Care Health Inc (OPCH), which reported mixed Q1 results and cut FY26 guidance, leading to a 21% decline; and Genprex Inc (GNPX), granted a patent for Reqorsa Gene Therapy but faced a 39% stock drop. These stocks are considered undervalued and may present trading opportunities.

benzinga_article

Medtronic

Option Care Health

Health Care Select Sector SPDR

SPDR S&P Health Equip

iShares US Medical Devices

iShares US Healthcare Providers

VG Health

SPDR S&P Health

iShares US Pharma

Top 3 Health Care Stocks That Are Set To Fly In Q2

Genprex announced that the Israel Patent Office granted a patent for its Reqorsa Gene Therapy in combination with PD-1 antibodies for cancer treatment. This patent strengthens Genprex's global intellectual property position, complementing existing patents in the U.S., Japan, China, and Europe. The company aims to address the rising lung cancer burden in Israel, highlighting the strategic importance of this patent for its future operations. Genprex focuses on developing gene therapies for cancer and diabetes, with Reqorsa targeting lung cancer markets worldwide.

Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel

Genprex has announced a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers for its Reqorsa Gene Therapy in lung cancer. The collaboration aims to enhance patient selection for ongoing clinical trials, Acclaim-1 and Acclaim-3, which have shown promising results. The company is positioning itself as a key player in gene therapy for oncology, with ongoing efforts to validate its treatments. Genprex's market cap is currently $11.58M, and it has released an updated investor presentation for stakeholders.

AstraZeneca

AstraZeneca PLC

Genprex Expands Lung Cancer Gene Therapy Research Collaboration

Genprex, Inc. announced that its research collaborators will present positive preclinical data on Reqorsa® Gene Therapy for lung cancer at the 2026 AACR Annual Meeting. The studies highlight biomarkers TROP2 and PTEN that may predict patient response to the therapy. The findings suggest that TROP2 and PTEN could guide therapeutic strategies in non-small cell lung cancer, enhancing patient selection and treatment efficacy. The presentations will take place on April 19, 2026, in San Diego, California, showcasing the potential of Reqorsa in cancer treatment.

prnewswire

iShares Global Healthcare

07:00 ETGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

COIN

DNUT

SMPL

Congressman Tim Moore (R-N.C.) is making headlines again for his stock trades in 2026, focusing on small-cap companies. He has recently bought shares in Genprex Inc and Simply Good Foods, alongside other trades including Krispy Kreme and Coinbase. Moore's trading history shows significant interest in small-cap stocks, having previously invested in Genprex and achieved a 52% gain in 2025, outperforming his peers and the S&P 500. Investors are advised to watch these stocks closely due to Moore's track record and the current market conditions.

- Congressman Tim Moore (R-N.C.) has been active in trading small-cap stocks, including significant purchases of Genprex and Simply Good Foods in 2025.  
- His trading activity has attracted attention, especially as he reported notable gains of 52% in 2025, outpacing both other Congress members and the S&P 500.  
- Investors are closely monitoring Moore's transactions and the performance of stocks he has invested in, particularly in the context of his focus on small-cap companies.

Coinbase

Invesco Food & Beverage ETF

Krispy Kreme

Simply Good Foods

Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying

KEYS

Genprex pre-market up 15.86%; Keysight Tech pre-market up 14.70%; Vir Biotechnology pre-market up 50.47%; Blue Hat pre-market up 37.99%; Silo Pharma pre-market up 31.93%

Price Alert

Keysight Tech

Hot pre-market trades in US stocks: Genprex up 15.86% pre-market; Keysight Tech up 14.70% pre-market

Genprex(GNPX.US)